Background
==========

Epidermal growth factor receptor (*EGFR*) mutations, such as deletions in exon 19 and point mutations in exon 21, are considered the most reliable predictive factors of outcome after treatment of non-small cell lung cancer (NSCLC) with EGFR tyrosine kinase inhibitors (EGFR-TKIs). Gefitinib was approved as a first-line therapy for NSCLC based on the results of a phase III landmark study, the Iressa Pan-Asia Study (IPASS), which showed that gefitinib conferred a survival benefit in *EGFR* mutation-positive patients over conventional chemotherapy \[[@B1]\]. The trial clearly showed that the selection of EGFR-TKIs should be based on molecular markers, not on clinical characteristics. Since then, given that many patients cannot receive second-line therapy after first-line failure because of their generally deteriorating condition, *EGFR* mutation testing is requested more frequently at the time of diagnosis for patients with adenocarcinoma. Indeed, a European workshop on *EGFR* mutation testing in NSCLC recommended testing at diagnosis, or at relapse, whenever possible, although no gold standard testing method was chosen \[[@B2]\].

Despite their importance in clinical practice, there is often too little tissue available to examine *EGFR* status as most are obtained by small needle biopsy or extracted from body fluids rather than via a more aggressive surgical approach. Many investigators have tried to solve this problem, leading to the development of more sensitive techniques to detect *EGFR* mutations, such as the scorpion-amplified refractory mutation system (SARMS) and the peptide nucleic acid (PNA)-mediated polymerase chain reaction (PCR) clamping method \[[@B3]-[@B18]\]. In addition, it is suggested that the plasma of cancer patients contains circulating free DNA (cfDNA) originating from necrotic tumor cells sloughed from the tumor mass or from circulating tumor cells \[[@B19]-[@B21]\]. Attempts to detect *EGFR* mutations in cfDNA using these sensitive techniques are currently in progress. If proven feasible and reliable, the cfDNA test may have broad clinical applications because it is non-invasive, convenient and can be performed repeatedly. In addition, the test could help diagnose lung cancer in cases when an adequate tissue sample is difficult to obtain. Over the past several years, many reports have shown promising results and have supported the feasibility of the test \[[@B22]-[@B33]\]. However, the optimal methodology for mutation detection from cfDNA and the possibility for the replacement of tumor tissue to blood sample still need to be confirmed.

In the present study, we examined the status of *EGFR* mutations in cfDNA isolated from plasma samples by a PNA-mediated PCR clamping method (PNA test) to determine the utility of plasma as a surrogate tissue for *EGFR* mutation analysis.

Methods
=======

Patients
--------

The prospective multicenter study was conducted to analyze *EGFR* mutations in plasma samples. Sixty patients with advanced NSCLC were recruited from 11 hospitals of the Korean Molecular Lung Cancer Group (KMLCG) between May 2010 and March 2011. All participants had histological or cytological confirmation of advanced NSCLC and showed a partial response to gefitinib as a second-line therapy without regard to the *EGFR* mutation status. Written informed consents for the use of their blood were obtained from all patients. The study protocol was approved by the Ethical Review Committee of 11 institutions (Korea Cancer Center Hospital, Korea University Guro Hospital, Daegu Catholic University Medical Center, Pusan National University Hospital, Inje University Busan Paik Hospital, Asan Medical Center, Wonkwang University Hospital, Chonnam National University Hwasun Hospital, Chonbuk National University Hospital, Chungnam National University Hospital, Hallym University Medical Center, Konkuk University Medical Center).

Plasma sample collection and DNA extraction
-------------------------------------------

Whole blood specimens from patients were collected in ethylenediaminetetraacetic acid tubes before and 2 months after the initiation of gefitinib administration and centrifuged at 3000 rpm for 5 minutes. The supernatants were collected and centrifuged at 3000 rpm for 5 minutes. The final supernatants were transferred to Eppendorf tubes and stored at −70°C until DNA extraction. DNA was extracted from 1--2 ml of supernatant with a DNeasy blood kit (Qiagen) according to the manufacturer's instructions. The final elution volume for DNA extraction was 60 μl and the amount of plasma DNA used for mutation testing was 30 ng.

PNA-mediated real-time PCR clamping method to detect deletions in EGFR exon 19 and L858R point mutations in EGFR exon 21
------------------------------------------------------------------------------------------------------------------------

Plasma DNA was analyzed using the PNAClamp^TM^ EGFR Mutation Detection kit (PANAGENE, Inc., Daejeon, Korea) as described in a previous retrospective study \[[@B34]\]. All reactions were conducted in a 20-μl volume using template DNA, primers and PNA probe set, and SYBR Green PCR master mix. All reagents were included in the kit. Real-time PCR reactions were performed using a CFX 96 instrument (Bio-Rad, USA). PCR cycling commenced with a 5 min hold at 94°C followed by 40 cycles at 94°C for 30 s, 70°C for 20 s, 63°C for 30 s, and 72°C for 30 s. Two *EGFR* mutation types were detected using PNA-mediated real-time PCR. The efficiency of PCR clamping was determined by measuring the cycle threshold (Ct) value. Ct values for the control and mutation assays were obtained by observing the SYBR Green amplification plots. The delta Ct (∆Ct) value was calculated (control Ct − sample Ct), ensuring that the sample and control Ct values were from the test and wild-type control samples. The cut-off ∆Ct was defined as 2 for both the G746_A750 deletion and the L858R point mutation.

Tumor mutation data
-------------------

At time of blood collection, we reviewed the *EGFR* mutation status in patient matched tumor tissue. By the direct sequencing used in routine practice at each institution to established *EGFR* mutation status in tumor tissue, forty tumor specimens were analyzed for *EGFR* mutations before gefitinib.

Statistical analyses
--------------------

The relationship between *EGFR* mutations and demographic and clinical features, including age, gender, histological type, performance status (PS), smoking status, TNM stage and response to gefitinib, was analyzed using Pearson's chi-square test or Fisher's exact test. Two-sided P values \<0.05 were considered statistically significant. All analyses were performed using SPSS version 17.0 (SPSS Inc., Chicago, IL, USA).

Results
=======

Patient characteristics
-----------------------

The clinical characteristics of the 60 patients are shown in Table [1](#T1){ref-type="table"}. The median age was 62.5 years (range: 38--84 years). Thirty-nine (65.0%) of the patients were female and 21 (35.0%) were male. Forty-three patients (71.7%) were non-smokers. Fifty patients (83.3%) had good PS. The most common histological subtype was adenocarcinoma (53 patients, 88.3%) and the majority of patients (88.3%) had stage IV disease. As aforementioned, all the patients received second-line gefitinib treatment and showed partial response.

###### 

Clinical characteristics of 60 patients

                                  **Total (n = 60)**
  ------------------------------ --------------------
  Age                                      
     Median, years                       62.5
     Range                              38-84
  Gender                                   
     Female                           39 (65.0%)
     Male                             21 (35.0%)
  Smoking history                          
     Nonsmoker                        43 (71.7%)
     Ex-smoker                        11 (18.3%)
     Current smoker                   6 (10.0%)
  WHO Performance status                   
     Normal activity                  23 (38.3%)
     Restricted activity              27 (45.0%)
     In bed \< 50% of the time        9 (15.0%)
     In bed \> 50% of the time         1 (1.7%)
  Tumor histology                          
     ADC                              53 (88.3%)
     SQC                               3 (5.0%)
     LCC                               1 (1.7%)
     NSCLC NOS                         2 (3.3%)
  Others                               1 (1.7%)
  Stage                                    
     IIIA                              3 (5.0%)
     IIIB                              4 (6.7%)
     IV                               53 (88.3%)

Abbreviations: *ADC* adenocarcinoma, *SQC* squamous cell carcinoma, *LCC* large cell carcinoma, *NSCLC NOS* non-small cell lung cancer not otherwise specified.

Detection of EGFR mutations in plasma
-------------------------------------

*EGFR* mutations were identified in 10/60 (16.7%) plasma samples by PNA testing. Of these, seven (70.0%) were in-frame deletions within exon 19 and three (30.0%) were arginine-to-leucine substitutions at amino acid 858 in exon 21 (L858R) (Table [2](#T2){ref-type="table"}). After 2 months of treatment, a repetition of the test in *EGFR* mutation-positive patients showed that none had *EGFR* mutations.

###### 

EGFR mutational status in plasma DNA samples

                           **Positive**   **Negative**
  ------------------------ -------------- --------------
  Exon 19 deletion         7 (70.0%)      \-
  Exon 21 point mutation   3 (30.0%)      \-

Comparison of matched tumor sequencing and plasma EGFR mutations
----------------------------------------------------------------

To evaluate the accuracy of the results of the PNA test, we compared plasma *EGFR* mutations with tumor sequencing in 40 paired donor-matched plasma and tumor tissue specimens. *EGFR* mutations were detected in the plasma samples of six (15.0%) patients, including four deletions in exon 19 and two point mutations in exon 21. In the donor-matched tumor tissues, 35 mutations were detected (87.5%) by using direct sequencing, including 18 in exon 19 and 17 in exon 21. Of the patients with plasma *EGFR* mutations, mutations of identical exon site were detected in the matched tumor tissues (Table [3](#T3){ref-type="table"}).

###### 

EGFR mutational status in the paired specimens of plasma and tumor tissue

  **N = 40**                 **Plasma EGFR mutation**       
  -------------------------- -------------------------- --- ----
  **Tissue EGFR mutation**   **positive**               6   29
                             **negative**               0   5

Correlation between EGFR mutation status assessed by PNA-mediated real-time PCR clamping and clinical features
--------------------------------------------------------------------------------------------------------------

*EGFR* mutations in plasma were detected more frequently in females (17.9% vs. 14.3% in male), non-smokers (18.6% vs. 11.8% in current/former smokers) and patients with stage IIIB disease (25.0% vs. 17.0% in stage IV). In addition, the overall mutation detection rate at the institute at which the central laboratory was located, and where sample processing did not require shipment, was relatively higher than that at the other institutes (23.8% vs. 12.8%); however, there were no statistically significant differences between the number of patients with *EGFR* mutations in plasma and those without (Table [4](#T4){ref-type="table"}).

###### 

Different characteristics according plasma EGFR mutational status

                                  **Patients with plasma EGFR mutation**   **Patients without plasma EGFR mutation**   ***P*value**
  ------------------------------ ---------------------------------------- ------------------------------------------- --------------
  Age                                                                                                                        
     Median, years                                 60.5                                      63.0                          0.76
     Range                                        51-76                                      38-84                    
  Gender                                                                                                                     
     Female                                     7 (70.0%)                                 32 (64.0%)                       1.00
     Male                                       3 (30.0%)                                 18 (36.0%)                  
  Smoking history                                                                                                            
     Nonsmoker                                  8 (80.0%)                                 35 (70.0%)                       0.67
     Ex-smoker                                  1 (10.0%)                                 10 (20.0%)                  
     Current smoker                             1 (10.0%)                                  5 (10.0%)                  
  WHO Performance status                                                                                                     
     Normal activity                            4 (40.0%)                                 19 (38.0%)                       0.94
     Restricted activity                        4 (40.0%)                                 23 (46.0%)                  
     In bed \< 50% of the time                  2 (20.0%)                                  7 (14.0%)                  
     In bed \> 50% of the time                      \-                                     1 (2.0%)                   
  Tumor histology                                                                                                            
     ADC                                        9 (90.0%)                                 44 (88.0%)                       0.83
     SQC                                            \-                                     3 (6.0%)                   
     LCC                                            \-                                     1 (2.0%)                   
     NSCLC NOS                                  1 (10.0%)                                  1 (2.0%)                   
     Others                                         \-                                     1 (2.0%)                   
  Stage                                                                                                                      
     IIIA                                           \-                                     3 (6.0%)                        0.64
     IIIB                                       1 (10.0%)                                  3 (6.0%)                   
     IV                                         9 (90.0%)                                 44 (88.0%)                  
  Central labotory                                                                                                           
     on-site                                    5 (50.0%)                                 16 (32.0%)                       0.30
     off-site                                   5 (50.0%)                                 34 (68.0%)                         

Abbreviations: *ADC* adenocarcinoma, *SQC* squamous cell carcinoma *LCC* large cell carcinoma, *NSCLC NOS* non-small cell lung cancer not otherwise specified.

Discussion
==========

Direct sequencing of amplified DNA products using Sanger's method is the most popular test for detecting *EGFR* mutations. However, this method is limited by low sensitivity (meaning that the mutant DNA must represent greater than 25% of the total DNA), and requires multiple steps to be performed over several days \[[@B15]\]. Furthermore, in patients with advanced NSCLC, tumor tissue is not always available for *EGFR* mutation testing either because only small amounts of tissue are collected or because the tissues collected have very low, or non-existent, tumor content . For these reasons, new techniques are needed for more sensitive and rapid detection. Several new techniques, including SARMS, Taqman PCR, and denaturing high-performance liquid chromatography (dHPLC) have been introduced, although none have been adopted as a standard method for detecting *EGFR* mutations \[[@B4],[@B5],[@B9]-[@B11],[@B13],[@B14],[@B16],[@B22]-[@B24],[@B26]-[@B28]\],\[[@B30]-[@B33]\].

Peptide nucleic acid (PNA) is an artificial polymer with the properties of both nucleic acids and proteins. PNA can bind tightly to complementary sequences in DNA because of a lack of electrostatic repulsion. Therefore, when a PNA oligomer, designed to detect an *EGFR* mutation and to bind to the antisense strand of the wild-type *EGFR* gene, is used for real-time PCR, amplification is rapid and sensitive and displays similar sensitivity to SARMS. Several studies using this novel method have been published \[[@B8],[@B17],[@B34],[@B35]\], however, to our knowledge, there are no reports showing detection of *EGFR* mutations in cfDNA extracted from the plasma of NSCLC patients using PNA-mediated real time PCR clamping.

In the present study, the detection rate of *EGFR* mutations in cfDNA was 16.1%. This is somewhat lower than that reported previously, which ranges from 20% to 73% (Table [5](#T5){ref-type="table"}) \[[@B16],[@B24],[@B26]-[@B28],[@B32]\]. Mutation detection rates can differ between subjects and between methods. Around 50--60% of Asian patients and 20--30% of Western patients with adenocarcinomas are expected to carry activating *EGFR* mutations, while a negligible proportion of patients with other lung cancer histology are expected to carry such mutations. Therefore, the *EGFR* mutation detection rate can be estimated from the clinical and demographic parameters, including race and histology, of the study subjects. If we assume that 50% of Asian adenocarcinoma patients carry *EGFR* mutations, the expected detection rate in an Asian study population comprising 80% adenocarcinoma patients should be 40%. In this context, the results of several previous studies suggesting that the *EGFR* mutation test in cfDNA might be equivalent to that in tissue exceed the expected rate of *EGFR* positivity. Hence, it is difficult to accept these although the tests used in those studies are highly sensitive and always performed with the utmost precision. In addition, other reports published detection rates around 20% \[[@B26],[@B27]\], which is similar to our report, and still *EGFR* mutation testing in cfDNA has not been introduced in clinical practice in spite of such promising results over several years. Therefore, more data are required to evaluate the suitability of the cfDNA test and assess whether it can replace the traditional tumor tissue test.

###### 

Previous reports on EGFR mutation test from circulating free DNA

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Year**                     **Authors**                       **Subjects**            **DNA concentration**                    **Mutation test**                                                        **Detection rate**
  ---------------------------- --------------------------------- ----------------------- ---------------------------------------- ------------------------------------------------------------------------ --------------------
  2006                         Kimura H, et al. \[[@B16]\]       Asian                   70 ng/mL (range, 0--1720 ng/mL)          SARMS                                                                    48.1% (13/27)

  Female : 37%                                                                                                                                                                                             

  Nonsmoker : N/A                                                                                                                                                                                          

  ADC : 85%                                                                                                                                                                                                

  ORR : 33%                                                                                                                                                                                                

  2008                         Maheswaran S, et al. \[[@B24]\]   Western                 N/A                                      SARMS                                                                    39% (7/18)

  EGFR mutant patients                                                                                                                                                                                     

  2009                         He C, et al. \[[@B29]\]           Asian                   N/A                                      Mutant-enriched PCR                                                      49.3% (66/134)

  Female : 37%                                                                                                                                                                                             

  Nonsmoker : 53%                                                                                                                                                                                          

  ADC : 75%                                                                                                                                                                                                

  2009                         Bai H, et al. \[[@B28]\]          Asian                   N/A                                      dHPLC                                                                    34.3% (79/230)

  Female : 46%                                                                                                                                                                                             

  Nonsmoker : 55%                                                                                                                                                                                          

  ADC : 74%                                                                                                                                                                                                

  ORR : 36% (37/102)                                                                                                                                                                                       

  2009                         Mack PC, et al. \[[@B26]\]        Western/Asian : 96/4%   2.3 ng/μL (range, 1--9 ng/μL )           SARMS                                                                    20% (10/49)

  Female : 56%                                                                                                                                                                                             

  Nonsmoker : 53%                                                                                                                                                                                          

  ADC : 67%                                                                                                                                                                                                

  2009                         Kuang Y, et al. \[[@B25]\]        Western                 52.3 ng/μL (range, 10--163 ng/μL )       SARMS and WAVE/Surveyor                                                  54% (29/54)

  Female : 81.5%                                                                                                                                                                                           

  Whole genome amplification                                                                                                                                                                               

  Nonsmoker : N/A                                                                                                                                                                                          

  ADC : N/A                                                                                                                                                                                                

  ORR : 56%                                                                                                                                                                                                

  2010                         Brevet M, et al. \[[@B31]\]       Western                 N/A                                      Mass spectrometry genotyping assay (Sequenom) and mutant-enriched PCR\   23.2% (10/31)
                                                                                                                                  Whole genome amplification                                               

  Female : 52%                                                                                                                                                                                             

  Nonsmoker : 45%                                                                                                                                                                                          

  ADC : 97%                                                                                                                                                                                                

  2010                         Jian G, et al. \[[@B27]\]         Asian                   N/A                                      Taqman PCR                                                               23.2% (13/56)

  Female : 46%                                                                                                                                                                                             

  Nonsmoker : 58%                                                                                                                                                                                          

  ADC : 78%                                                                                                                                                                                                

  ORR : 30%                                                                                                                                                                                                

  2011                         Jiang B, et al. \[[@B30]\]        Asian                   Minimum 4 ng/μL (range, 11--66 ng/μL )   Mutant-enriched PCR                                                      31% (18/58)

  Female : 31%                                                                                                                                                                                             

  Nonsmoker : 38%                                                                                                                                                                                          

  ADC : 72%                                                                                                                                                                                                

  2011                         Taniguchi K, et al. \[[@B32]\]    Asian                   N/A                                      BEAMing                                                                  72.7% (32/44)

  EGFR mutant patients                                                                                                                                                                                     

  This study                   Kim HR, et al.                    Asian                   8.6 ng/μL                                PNA-based PCR clamping                                                   16.7% (10/60)

  Female : 65%                                                                                                                                                                                             

  Nonsmoker : 2%                                                                                                                                                                                           

  ADC : 88%                                                                                                                                                                                                

                                                                 ORR : 100%                                                                                                                                 
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Abbreviations: *ADC* adenocarcinoma, *SARMS* scorpion-amplified refractory mutation system, *PCR* polymerase chain reaction, *dHPLC* denaturing high-performance liquid chromatography, *BEAMing* beads, emulsion, amplification, and magnetics, *PNA* peptide nucleic acid.

The T790M mutation was not detected in any of the samples that were positive for activating *EGFR* mutations, although one report showed that low levels of T790M were detected in pretreatment tumor samples from 10/26 patients (38%) \[[@B24]\]. The detection rate of T790M seems to be closely associated with the sensitivity of the *EGFR* mutation test. A study using the BEAMing (beads, emulsion, amplification, and magnetics) method showed that the proportion of T790M within activating mutations ranged from 13.3--94.0%, and calculated that the T790M peak within the mutant allele fraction would range from 0.1--1% in cfDNA \[[@B32]\]. Therefore, even with a higher sensitivity permitting detection of 1% mutant DNA, as is reached with SARMS and PNA-based PCR clamping, detection of the T790M mutation in cfDNA remains difficult. This suggests that circulating tumor cells (CTC) would be a better alternative source material in which to detect the T790M mutation, and for predicting progression-free survival.

None of the *EGFR* mutations initially detected in cfDNA before treatment were detected 2 months after EGFR-TKI therapy and partial response. Since the initial tumor size and stage did not correlate with the detection rate, this result suggests that the amount of actively proliferating tumor cells, rather than the tumor burden, could affect the amount of circulating tumor DNA. Accordingly, in a previous CTC study, a 50% decline in CTCs within 1 week was noted in one patient, with the nadir reached 3 months after treatment, while the number of CTCs increased at the time of clinical progression and declined again when the tumor responded to subsequent chemotherapy \[[@B24]\]. It was also evident that, although CTC detection was not associated with initial tumor burden, there was a close concordance between tumor response and the number of CTCs during treatment.

Finally, our results suggest that better processing of plasma samples and on-site testing without necessity of sample delivery can improve detection rate.

In summary, our results show that, although detection of *EGFR* mutations in cfDNA is possible in some patients, more data are required to evaluate clinical applicability. Technical advances in sensitivity, stability and standardization are also needed, as well as adequate sample processing.
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